Isoconazole nitrate is a broad-spectrum antimicrobial agent with both potent antifungal properties and effectiveness against gram-positive bacteria. Initially patented in 1968 and approved for medical use in 1979, this azole antifungal drug has earned its place in dermatological and gynecological treatments across many countries worldwide.
For foot and vaginal infections, isoconazole has demonstrated similar effectiveness to clotrimazole, making it a valuable option in the pharmacological arsenal against common fungal conditions1. As a highly effective antimycotic with additional antibacterial activity, isoconazole nitrate offers rapid absorption rates and low systemic exposure potential, contributing to its favorable safety profile in topical applications.
Chemical Structure and Properties
Isoconazole belongs to the imidazole derivative family and is structurally related to clotrimazole. Its chemical name is 1-[2-(2,4-dichlorophenyl)-2-[(2,6-dichlorophenyl)methoxy]ethyl]-1H-imidazole nitrate. The base compound has a molecular formula of C18H14Cl4N2O with a molar mass of 416.12 g·mol−1, while the nitrate salt has the formula C18H15Cl4N3O4.
From a chemical taxonomy perspective, isoconazole belongs to the class of organic compounds known as benzylethers, which are aromatic ethers with the general formula ROCR’ (where R = alkyl, aryl; R’ = benzene). This specific structure contributes to isoconazole’s ability to penetrate fungal cell membranes and interfere with essential cellular components, explaining its broad antimicrobial activity spectrum.
Isoconazole-Based Medicines List
Isoconazole nitrate is available in various formulations under different brand names across global markets:
- Travogen – A primary brand name for isoconazole nitrate cream (Bayer)
- Gyno-Travogen – Vaginal suppository/pessary formulation for treating vaginal mycoses (Bayer/Schering)
- Travocort – Combination product containing isoconazole nitrate and diflucortolone valerate, used for inflammatory fungal skin infections
- Icaden – Marketed in Brazil, Uruguay, and Mexico (Bayer)
- Albacort – Combination with diflucortolone (Liva Ilac, Turkey)
- Azonit – Marketed in Lebanon (Pharma International)
- Fungoid – Combination with diflucortolone (Turkey)
- Fuggy – Combination with diflucortolone valerate (Abdi Ibrahim, Turkey)
Mechanism of Action
The antimicrobial action of isoconazole nitrate mirrors that of other N-substituted imidazole derivatives. Its primary antifungal mechanism involves attaching to fungal cell membranes and blocking the production of ergosterol, a type of sterol that fungi require for survival. This interference leads to increased membrane permeability and eventual cell death. Research has demonstrated that isoconazole causes rapid reduction in ATP concentrations through damage to the fungal cell membrane.
Additionally, it interacts with the cell wall, causing convolutions and wrinkles that further compromise structural integrity. Isoconazole also inhibits the enzyme-catalyzed release of spheroplasts from young yeast cells, preventing proper cell division and growth. This multifaceted approach explains isoconazole’s effectiveness against various pathogens, including dermatophytes, pathogenic yeasts, filamentous fungi, and gram-positive bacteria.
Pharmacokinetics and Pharmacodynamics
Isoconazole nitrate demonstrates excellent penetration properties when applied topically. Studies show it penetrates rapidly into human skin, reaching maximum drug concentrations in both the horny layer and living skin within just one hour after application. These high concentrations are maintained for at least 7 hours, with measurements showing approximately 3500 μg/ml in the horny layer (corresponding to 7 mmol/l), 20 μg/ml in living epidermis (40 μmol/l), and 3 μg/ml in the dermis (6 μmol/l).
Particularly noteworthy is isoconazole’s ability to create a large and long-lasting reservoir in the horny layer of the skin. This reservoir can remain for up to 10 days after treatment, potentially providing protection against new infections. For vaginal applications, negligible systemic absorption occurs following intravaginal insertion of two 300-mg pessaries. Fungicidal concentrations persist in the vagina for approximately 3 days after a single dose of 600 mg inserted intravaginally, explaining why single-dose treatment regimens are effective for vaginal candidiasis.
Therapeutic Uses
Isoconazole nitrate has proven effective in treating various fungal and bacterial infections:
| Condition | Formulation | Dosage | Duration | Efficacy |
|---|---|---|---|---|
| Vaginal candidiasis (thrush) | Pessary/Suppository | 600 mg single dose | One-time application | 80-90% clinical and mycological cure rate |
| Superficial fungal skin infections | Cream (1%) | Applied once or twice daily | 2-3 weeks typically | Effective against dermatophytes and yeasts |
| Inflammatory dermatomycoses | Combination with diflucortolone (Travocort) | Applied twice daily | Maximum 2 weeks | Faster relief of inflammation and itch |
| Athlete’s foot (tinea pedis) | Cream | Applied once daily | 2-4 weeks | Effective, especially treatment-resistant cases |
| Interdigital space infections | Cream | Apply and place gauze between toes | 2-3 weeks | Particularly effective for persistent cases |
| Erythrasma | Cream | Applied once daily | 2-3 weeks typically | Effective against causative organism |
| Gram-positive bacterial infections | Various formulations | As directed | Condition-dependent | Effective antibacterial action |
Side Effects and Adverse Reactions
Isoconazole nitrate is generally well-tolerated, but some adverse reactions may occur during treatment. The most commonly reported side effects include mild and transient local reactions like vaginal burning, itching, and redness at the application site. Application site irritation and burning are the most frequently observed adverse reactions in clinical studies. These reactions are typically mild and resolve without intervention.
Some patients may develop contact dermatitis in rare cases, including an unusual papulopustular reaction that has been documented in medical literature. When used in combination with corticosteroids (as in Travocort), potential corticosteroid-related adverse reactions should be considered, particularly with extensive or prolonged use. These might include local skin atrophy, telangiectasia, or other side effects associated with topical corticosteroids. Overall, the topical nature of isoconazole preparations contributes to its favorable safety profile with minimal systemic effects.
Drug Interactions
Due to the minimal systemic absorption of topical isoconazole nitrate, significant drug interactions with oral medications are unlikely. However, an important practical consideration exists for vaginal applications: isoconazole may damage rubber or latex products such as condoms or diaphragms. This interaction can potentially compromise the effectiveness of these contraceptive methods. Consequently, patients using vaginal formulations of isoconazole nitrate should be advised to use alternative contraceptive methods during treatment and for several days afterward.
When using isoconazole in combination with other topical medications, patients should consult healthcare professionals to determine if simultaneous application is appropriate. This precaution helps prevent potential incompatibilities between different topical preparations that might reduce therapeutic efficacy or increase the risk of adverse reactions.
Safety Considerations
Special considerations should be made regarding the use of isoconazole nitrate during pregnancy and lactation. While topical antifungals generally have minimal systemic absorption, the safety profile for pregnant or breastfeeding women should be assessed on a case-by-case basis. For Travocort (combination with diflucortolone valerate), adverse reactions cannot be excluded in neonates whose mothers have been treated extensively or for a prolonged period during pregnancy or while lactating-potential risks include reduced adrenocortical function and immunosuppression.
Application over large areas or under occlusive conditions may increase systemic absorption, particularly for combination products containing corticosteroids. Patients should follow prescribed application instructions carefully to minimize potential risks.
For persistent infections or those unresponsive to treatment, medical reevaluation is recommended to confirm the diagnosis and consider alternative therapeutic approaches. Regular personal hygiene is described as essential for successful treatment, particularly for conditions like athlete’s foot, where thoroughly drying between toes and changing socks daily is advised.
Regulatory Status
Isoconazole nitrate has been approved and marketed in numerous countries worldwide since its introduction in 1979. It is available in Europe, Asia, Latin America, and other regions, primarily as a topical antifungal agent for dermatological and gynecological applications. Despite its global presence, isoconazole has not received approval in the United States, where similar azole antifungals like clotrimazole and miconazole dominate the market.
The drug is primarily marketed as a once-daily topical anti-Candida agent, with strong clinical evidence supporting its efficacy. Studies evaluating isoconazole have consistently demonstrated that 80-90% of patients with vaginal candidiasis who were treated once daily with the drug remained clinically and mycologically cured. This high success rate, combined with convenient dosing, has contributed to isoconazole’s continued presence in international markets for over four decades.
Conclusion
Isoconazole nitrate represents an important contribution to the antifungal therapeutic arsenal, offering broad-spectrum coverage against multiple pathogens with excellent topical efficacy. Its dual action against fungi and gram-positive bacteria makes it particularly valuable for mixed infections or conditions where bacterial superinfection is a concern.
The pharmacokinetic profile of isoconazole, characterized by rapid skin penetration and long-lasting reservoir effects, allows for convenient dosing schedules that promote patient adherence.
The combination products containing isoconazole and corticosteroids provide accelerated symptom relief for inflammatory fungal conditions while maintaining antimicrobial effectiveness. While not available in all global markets, isoconazole nitrate continues to be a trusted treatment option in many countries, providing clinicians with a reliable tool for managing common fungal infections of the skin and vaginal mucosa.
As with all medications, appropriate patient selection, proper administration techniques, and consideration of possible adverse effects remain essential for optimizing therapeutic outcomes with isoconazole nitrate.
